315 related articles for article (PubMed ID: 31477841)
1. Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer.
Wei TT; Lin YT; Tang SP; Luo CK; Tsai CT; Shun CT; Chen CC
Oncogene; 2020 Jan; 39(2):414-427. PubMed ID: 31477841
[TBL] [Abstract][Full Text] [Related]
2. Liensinine sensitizes colorectal cancer cells to oxaliplatin by targeting HIF-1α to inhibit autophagy.
Feng Z; Zhang S; Han Q; Chu T; Wang H; Yu L; Zhang W; Liu J; Liang W; Xue J; Wu X; Zhang C; Wang Y
Phytomedicine; 2024 Jul; 129():155647. PubMed ID: 38703660
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia Induces Drug Resistance in Colorectal Cancer through the HIF-1α/miR-338-5p/IL-6 Feedback Loop.
Xu K; Zhan Y; Yuan Z; Qiu Y; Wang H; Fan G; Wang J; Li W; Cao Y; Shen X; Zhang J; Liang X; Yin P
Mol Ther; 2019 Oct; 27(10):1810-1824. PubMed ID: 31208913
[TBL] [Abstract][Full Text] [Related]
5. miR-148a inhibits early relapsed colorectal cancers and the secretion of VEGF by indirectly targeting HIF-1α under non-hypoxia/hypoxia conditions.
Tsai HL; Miao ZF; Chen YT; Huang CW; Yeh YS; Yang IP; Wang JY
J Cell Mol Med; 2019 May; 23(5):3572-3582. PubMed ID: 30834693
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
7. The novel hypoxia-inducible factor-1α inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth.
Ban HS; Kim BK; Lee H; Kim HM; Harmalkar D; Nam M; Park SK; Lee K; Park JT; Kim I; Lee K; Hwang GS; Won M
Cell Death Dis; 2017 Jun; 8(6):e2843. PubMed ID: 28569777
[TBL] [Abstract][Full Text] [Related]
8. HIF-1α in colorectal carcinoma: review of the literature.
Ioannou M; Paraskeva E; Baxevanidou K; Simos G; Papamichali R; Papacharalambous C; Samara M; Koukoulis G
J BUON; 2015; 20(3):680-9. PubMed ID: 26214618
[TBL] [Abstract][Full Text] [Related]
9. Induction of lncRNA NORAD accounts for hypoxia-induced chemoresistance and vasculogenic mimicry in colorectal cancer by sponging the miR-495-3p/ hypoxia-inducible factor-1α (HIF-1α).
Zhang L; Wu H; Zhang Y; Xiao X; Chu F; Zhang L
Bioengineered; 2022 Jan; 13(1):950-962. PubMed ID: 34969360
[TBL] [Abstract][Full Text] [Related]
10. Jianpi Jiedu decoction, a traditional Chinese medicine formula, inhibits tumorigenesis, metastasis, and angiogenesis through the mTOR/HIF-1α/VEGF pathway.
Peng W; Zhang S; Zhang Z; Xu P; Mao D; Huang S; Chen B; Zhang C; Zhang S
J Ethnopharmacol; 2018 Oct; 224():140-148. PubMed ID: 29852266
[TBL] [Abstract][Full Text] [Related]
11. Sestrin2 inhibits hypoxia-inducible factor-1α accumulation via AMPK-mediated prolyl hydroxylase regulation.
Seo K; Seo S; Ki SH; Shin SM
Free Radic Biol Med; 2016 Dec; 101():511-523. PubMed ID: 27840318
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-143 inhibits tumor growth and angiogenesis and sensitizes chemosensitivity to oxaliplatin in colorectal cancers.
Qian X; Yu J; Yin Y; He J; Wang L; Li Q; Zhang LQ; Li CY; Shi ZM; Xu Q; Li W; Lai LH; Liu LZ; Jiang BH
Cell Cycle; 2013 May; 12(9):1385-94. PubMed ID: 23574723
[TBL] [Abstract][Full Text] [Related]
13. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
[TBL] [Abstract][Full Text] [Related]
14. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-induced vasculogenic mimicry formation in human colorectal cancer cells: Involvement of HIF-1a, Claudin-4, and E-cadherin and Vimentin.
Li W; Zong S; Shi Q; Li H; Xu J; Hou F
Sci Rep; 2016 Nov; 6():37534. PubMed ID: 27869227
[TBL] [Abstract][Full Text] [Related]
16. Chrysin inhibits expression of hypoxia-inducible factor-1alpha through reducing hypoxia-inducible factor-1alpha stability and inhibiting its protein synthesis.
Fu B; Xue J; Li Z; Shi X; Jiang BH; Fang J
Mol Cancer Ther; 2007 Jan; 6(1):220-6. PubMed ID: 17237281
[TBL] [Abstract][Full Text] [Related]
17. Ursolic acid sensitized colon cancer cells to chemotherapy under hypoxia by inhibiting MDR1 through HIF-1α.
Shan JZ; Xuan YY; Zhang Q; Huang JJ
J Zhejiang Univ Sci B; 2016 Sep; 17(9):672-82. PubMed ID: 27604859
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic and anti-proliferative effects of inhibition of HIF-1α by p-HIF-1α RNAi in colorectal cancer.
Qiu YY; Hu SJ; Bao YJ; Liang B; Yan CN; Shi XJ; Yu H; Zou Y; Tang LR; Tang QF; Feng W; Yin PH
Int J Clin Exp Pathol; 2015; 8(7):7913-20. PubMed ID: 26339356
[TBL] [Abstract][Full Text] [Related]
19. Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.
Paradziej-Łukowicz J; Skwarska A; Peszyńska-Sularz G; Brillowska-Dąbrowska A; Konopa J
Cancer Biol Ther; 2011 Oct; 12(7):586-97. PubMed ID: 21775820
[TBL] [Abstract][Full Text] [Related]
20. NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction.
Kim KH; Kim D; Park JY; Jung HJ; Cho YH; Kim HK; Han J; Choi KY; Kwon HJ
J Mol Med (Berl); 2015 May; 93(5):499-509. PubMed ID: 25471482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
